{
    "clinical_study": {
        "@rank": "158282", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give Lamisil to\n      HIV-positive patients with thrush (a fungal infection) that has not responded to\n      fluconazole."
        }, 
        "brief_title": "Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment", 
        "condition": [
            "Candidiasis, Oral", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis", 
                "Candidiasis, Oral", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, dose-escalating study with up to 2 sequential cohorts. The first 15\n      patients receive Lamisil for 2 weeks. After 2 weeks, patients considered clinically cured\n      (i.e., absence of removable, white plaques) are removed from treatment; patients not\n      considered clinically cured receive an additional 2 weeks of treatment. At the end of 4\n      weeks, treatment is discontinued, regardless of clinical cure outcome. If less than 80% of\n      patients are clinically cured after the 4 weeks of treatment, a second cohort of 15 patients\n      receive Lamisil on the same treatment regimen as first cohort (i.e., initial 2-week\n      treatment period, with an additional 2 weeks of treatment for those patients who are not\n      considered clinically cured after 2 weeks of treatment)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are at least 18 years old.\n\n          -  Have thrush that has not responded to at least 10 days of fluconazole treatment.\n\n          -  Are HIV-positive.\n\n          -  Are expected to live at least 4 weeks.\n\n          -  Are able to take oral medication.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Have liver or kidney disease.\n\n          -  Have received certain medications.\n\n          -  Have a history of serious diarrhea or digestive problems.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002394", 
            "org_study_id": "282A", 
            "secondary_id": "SFS 257-E-00"
        }, 
        "intervention": {
            "intervention_name": "Terbinafine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Terbinafine"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Dose-Response Relationship, Drug", 
            "Fluconazole", 
            "Antifungal Agents", 
            "Candidiasis, Oral", 
            "Drug Administration Schedule", 
            "terbinafine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33308"
                    }, 
                    "name": "Therafirst Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33901"
                    }, 
                    "name": "Associates in Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tamarac", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33321"
                    }, 
                    "name": "Clireco Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33614"
                    }, 
                    "name": "Infectious Diseases Research Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / Division of Infectious Disease"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "071029880"
                    }, 
                    "name": "Saint Michaels Med Ctr / Infectious Disease Resch Dpt"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "St Vincents Hosp / Clinical Research Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "Univ of Texas Med Branch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampton", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23666"
                    }, 
                    "name": "Hampton Roads Med Specialists"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Four-Week, Open-Label, Non-Randomized, Multicenter, Dose-Finding, Pilot Study to Evaluate the Safety and Efficacy of Two Daily Doses of Lamisil (1500 Mg and 2000 Mg), Administered for a Maximum of 4 Weeks in HIV-Positive Subjects With Oral Mucosal Candidiasis Not Having Responded to a Minimum of 200 Mg Fluconazole Monotherapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002394"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1999"
    }, 
    "geocoordinates": {
        "Associates in Research": "26.641 -81.872", 
        "Clireco Inc": "26.213 -80.25", 
        "Hampton Roads Med Specialists": "37.03 -76.345", 
        "Infectious Diseases Research Inc": "27.951 -82.457", 
        "Northwestern Univ / Division of Infectious Disease": "41.878 -87.63", 
        "Saint Michaels Med Ctr / Infectious Disease Resch Dpt": "40.736 -74.172", 
        "St Vincents Hosp / Clinical Research Program": "40.714 -74.006", 
        "Therafirst Med Ctr": "26.122 -80.143", 
        "Univ of Texas Med Branch": "29.301 -94.798"
    }
}